+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
MANKIND

Mankind Pharma Share Price

₹2,425.00 -13 (-0.53%)
26.98% Gain from 52W Low

11 Aug, 2026 3:55 PM (IST)

Mankind Pharma live price: ₹2,425.00. It opened at ₹2,429 vs previous close ₹2,438; intraday high/low: ₹2,440/₹2,406. The 50 & 200 DMA stand at ₹2,463.90/₹2,356.40.

Mankind Pharma Performance

  • Today's Low
  • ₹2,406
  • Today's High
  • ₹2,440
  • 52 Week Low
  • ₹1,910
  • 52 Week High
  • ₹2,674
  • Open Price₹2,429
  • Previous Close₹2,438
  • Volume236,310
  • 50 DMA₹2,463.90
  • 100 DMA₹2,399.40
  • 200 DMA₹2,356.40

Mankind Pharma Chart

Investment Returns

  • Over 1 Month -3.96%
  • Over 3 Month -1.77%
  • Over 6 Month + 16.2%
  • Over 1 Year -0.51%

Smart Investing Starts Here Start SIP with Mankind Pharma for Steady Growth!

Invest Now

Mankind Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 49
  • PEG Ratio
  • 6.2
  • Market Cap Cr
  • 100,152
  • P/B Ratio
  • 6.1
  • Average True Range
  • 61.5
  • EPS
  • 49.5
  • Dividend Yield
  • 0
  • MACD Signal
  • -16.3
  • RSI
  • 42.12
  • MFI
  • 28.58

Latest Stock News Updates

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Change in Management

Please find attached intimation regarding appointment of Mr. Anish Vanraj Bafna as Additional Director designated as Non-Executive Independent Director

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Change in Management

Please find attached intimation regarding appointment of Mr. Anish Vanraj Bafna as Additional Director designated as Non-Executive Independent Director

Mankind Pharma Ltd - 543904 - Board Meeting Outcome for For Appointment Of An Additional Director Designated As Non-Executive Independent Director

Please find attached outcome of board meeting

Mankind Pharma Financials

Mankind Pharma Technicals

EMA & SMA

Current Price
₹2,425.00
-13 (-0.53%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹2,486.20
  • 50 Day
  • ₹2,463.90
  • 100 Day
  • ₹2,399.40
  • 200 Day
  • ₹2,356.40

Resistance and Support

2423.37 Pivot Speed
  • R3 2,475.30
  • R2 2,457.50
  • R1 2,441.20
  • S1 2,407.10
  • S2 2,389.30
  • S3 2,373.00

Mankind Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-30 Quarterly Results
2026-05-19 Audited Results
2026-02-03 Quarterly Results
2025-11-06 Quarterly Results
2025-07-31 Quarterly Results & Interim Dividend
Date Purpose Remarks
2025-08-08 INTERIM Rs.1.00 per share(100%)Interim Dividend
View Mankind Pharma Dividend History Arrow

Mankind Pharma F&O

Mankind Pharma Shareholding Pattern

72.63%
10.87%
9.45%
4.52%
2.53%

About Mankind Pharma

Mankind Pharma engaged in the manufacturing and trading of pharmaceuticals and health care products. The Company has three manufacturing facilities at Paonta Sahib in the state of Himachal Pradesh, one manufacturing facility in state of Sikkim, two manufacturing facilities in state of Rajasthan, one manufacturing facility in state of Andhra Pradesh, three in-house research and development centres in the state of Haryana and one research and development centre in the state of Maharashtra to carry out research in pharmaceutical products. View More
  • NSE Symbol
  • MANKIND
  • BSE Symbol
  • 543904
  • ISIN
  • INE634S01028

Similar Stocks to Mankind Pharma

Mankind Pharma FAQs

Mankind Pharma share price is ₹2,425 As on 12 August, 2026 | 08:13

The Market Cap of Mankind Pharma is ₹100151.5 Cr As on 12 August, 2026 | 08:13

The P/E ratio of Mankind Pharma is 49 As on 12 August, 2026 | 08:13

The PB ratio of Mankind Pharma is 6.1 As on 12 August, 2026 | 08:13

The 52 week High & Low of Mankind Pharma is ₹2674/₹1909.7 respectively As on 12 August, 2026 | 08:13

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23